• Home
• Contact us
• About us

You are here: Home » News » Industry news » AstraZeneca extends its investment in Russia with new predictive science centre in St Petersburg

AstraZeneca extends its investment in Russia with new predictive science centre in St Petersburg

Publication date: 16 June 2011
Author: AstraZeneca

Tagged with: AstraZeneca, David Brennan

AstraZeneca announced today that it plans to establish a Predictive Science Centre in St. Petersburg over the coming year. The move strengthens AstraZeneca’s investments in Russia and supports the Russian Government’s strategy to modernise and develop the country’s pharmaceutical sector.

The new AstraZeneca Predictive Science Centre, the company’s first in Russia, will leverage local scientific talent and focus on developing bioinformatics, data analysis methods, software and systems to better predict the safety and efficacy of potential new medicines. Approximately 30 people will work at the Centre through collaborations with local companies and organisations as part of a related agreement with the St. Petersburg government to be announced later this week.

Earlier this year, the company began construction of a new $150 million manufacturing facility in the Kaluga region to supply Russia with innovative AstraZeneca medicines that are locally manufactured. In addition, AstraZeneca has established several partnerships with Russian development institutes, including the Skolkovo Innovation Centre and Russia Venture Company, to share its global R&D expertise through research collaborations, grant programs, and clinical trials.

The new R&D and manufacturing investments, combined with the growing operational sales and marketing capabilities and an increased clinical research focus in Russia, reinforce AstraZeneca’s long term commitment to the country and constitute a significant contribution to the Russian economy of $1.2 billion over the next five years.

Speaking today at the St. Petersburg International Economic Forum in Russia, David Brennan, Chief Executive of AstraZeneca, said: “Russia is a dynamic economy where our growing investments will help us to offer to patients AstraZeneca’s portfolio of innovative medicines. We are pleased to contribute to the development of an innovative healthcare sector through our local research and manufacturing capabilities, established operations, and scientific and educational collaborations.”

In-depth focus:
Mass Spectrometry

This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:

• Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
• Quantification of membrane drug transporters and application in drug discovery and development
• Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable

Download the PDF here >>

Company directory

ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |

Add your company, it's free >>